Interferon-induced transmembrane protein 5 (IFITM5)

Interferon-induced transmembrane protein 5 (IFITM5, also known as BRIL) is a small, bone-specific transmembrane protein expressed mainly in osteoblasts and plays a central role in bone mineralization[1][2][3]. It is unique among IFITM family members for its strict bone expression and absence of interferon inducibility; its physiological function remains incompletely understood. Mutations in IFITM5 cause autosomal dominant osteogenesis imperfecta type V and VI, which manifest as brittle bone and abnormal skeletal development. The protein is not known to be a direct target of current drugs, but its role as a cell surface marker and genetic disease locus makes it significant in bone biology and disease research[1][2][3].

Other names

IFITM5BRILDSPA1fragilis4Hrmp1OI5bone-restricted interferon-induced transmembrane protein-like proteinbone-restricted IFITM-like proteindispanin subfamily A member 1

No direct drug mechanisms established. Disease-causing mutations result in neomorphic protein functions (e.g., gain-of-function/ectopic mineralization, impaired matrix formation in OI)